Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Eriko Katsuta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5862-2919; OpenAlex author ID A5079949414. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 8

  1. CD73 is associated with glycolysis related metabolic programs and CD8+ T cell suppression in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2026.1873813↗
  2. Treatment of initially unresectable local advanced pancreatic adenocarcinoma with FOLFIRINOX: A prospective study YCOG1403 (C-FLAP study). Co-author DOI 10.1038/s41598-025-23608-5↗
  3. Late-Onset Para-Aortic Lymph Node Recurrence 11 Years after Resection of Pancreatic Cancer: Histological Reassessment Revealed Neuroendocrine Differentiation A… Co-author DOI 10.70352/scrj.cr.25-0374↗
  4. A prognostic score based on long-term survivor unique transcriptomic signatures predicts patient survival in pancreatic ductal adenocarcinoma. Co-author PMID 34659888↗
  5. Transcriptomic Profile of Lymphovascular Invasion, a Known Risk Factor of Pancreatic Ductal Adenocarcinoma Metastasis. First author DOI 10.3390/cancers12082033↗
  6. Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms21113890↗
  7. High expression of Annexin A2 is associated with DNA repair, metabolic alteration, and worse survival in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.surg.2019.04.011↗
  8. Host sphingosine kinase 1 worsens pancreatic cancer peritoneal carcinomatosis. Co-author DOI 10.1016/j.jss.2016.05.034↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kazuaki Takabe · 6 shared papers, 2016–2026 · strength 1.02
  2. Daisuke Ban · 2 shared papers, 2025–2026 · strength 0.55
  3. Li Yan · 2 shared papers, 2020–2021 · strength 0.33
  4. Hideo Takahashi · 2 shared papers, 2019–2020 · strength 0.26
  5. Daisuke Asano · 1 shared paper, 2025 · strength 0.24
  6. Yohei Tabe · 1 shared paper, 2025 · strength 0.24
  7. Kensuke Kubota · 1 shared paper, 2025 · strength 0.22
  8. Ryutaro Mori · 1 shared paper, 2025 · strength 0.22
  9. Kentaro Miyake · 1 shared paper, 2025 · strength 0.22
  10. Yasushi Ichikawa · 1 shared paper, 2025 · strength 0.22
  11. Noritoshi Kobayashi · 1 shared paper, 2025 · strength 0.22
  12. Yasuhiro Yabushita · 1 shared paper, 2025 · strength 0.22
  13. Itaru Endo · 1 shared paper, 2025 · strength 0.22
  14. Omar Maen Rashid · 1 shared paper, 2020 · strength 0.19
  15. Matthew H. G. Katz · 1 shared paper, 2020 · strength 0.13
  16. Hiroaki Aoki · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.